Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Third Harmonic Bio, Inc.
THB335 is a highly potent and selective inhibitor of the receptor tyrosine kinase KIT that is expressed on mast cells.
The study will evaluate the safety, pharmacokinetics, pharmacodynamics, and food effect profile of THB335 administered orally in healthy participants.
Age
18–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
In good health, determined by no clinically significant findings from medical history, 12 lead electrocardiogram (ECG), vital sign measurements, and clinical laboratory evaluations
Males or females, of any race, between 18 and 65 years of age, inclusive.
Participants must understand the nature of the study and must provide signed and dated written informed consent in accordance with local regulations before the conduct of any study related procedures
Body weight of ≥ 50.0 kg for men and ≥ 45.0 kg for women and Body Mass Index (BMI) of 17.5-32.0 kg/m2 (inclusive) at Screening
You may not be if
Significant history or clinical manifestation of cancer or any metabolic, allergic, dermatological, hepatic, biliary, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder
Vaccinated within 14 days prior to Day -1 or intention to receive vaccination during the study
A positive urine drug screen/alcohol breath test
The participant currently smokes, vapes, or uses nicotine-containing products.
